Matinas BioPharma Holdings, Inc. (MTNB)
MTNB Stock Price Chart
Explore Matinas BioPharma Holdings, Inc. interactive price chart. Choose custom timeframes to analyze MTNB price movements and trends.
MTNB Company Profile
Discover essential business fundamentals and corporate details for Matinas BioPharma Holdings, Inc. (MTNB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jul 2014
Employees
3.00
Website
https://www.matinasbiopharma.comCEO
Jerome D. Jabbour
Description
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
MTNB Financial Timeline
Browse a chronological timeline of Matinas BioPharma Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 11 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$1.03 .
Earnings released on 15 Apr 2025
EPS came in at -$1.68 falling short of the estimated -$0.78 by -115.38%.
Earnings released on 26 Mar 2025
EPS came in at -$1.50 falling short of the estimated -$0.78 by -92.31%, while revenue for the quarter reached $962.00K .
Earnings released on 13 Nov 2024
EPS came in at -$0.85 surpassing the estimated -$1.05 by +19.05%.
Stock split effective on 3 Sept 2024
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2024
EPS came in at -$1.00 falling short of the estimated -$0.83 by -20.00%.
Earnings released on 9 May 2024
EPS came in at -$1.50 falling short of the estimated -$0.03 by -4.90K%.
Earnings released on 27 Mar 2024
EPS came in at -$1.50 falling short of the estimated -$1.13 by -33.33%, while revenue for the quarter reached -$1.10M , missing expectations by -465.33%.
Earnings released on 8 Nov 2023
EPS came in at -$1.50 falling short of the estimated -$0.03 by -4.90K%.
Earnings released on 9 Aug 2023
EPS came in at -$1.50 falling short of the estimated -$0.03 by -4.90K%.
Earnings released on 10 May 2023
EPS came in at -$1.50 matching the estimated -$1.50, while revenue for the quarter reached $1.10M , beating expectations by +265.33%.
Earnings released on 15 Mar 2023
EPS came in at -$1.00 matching the estimated -$1.00, while revenue for the quarter reached $1.06M , missing expectations by -3.36%.
Earnings released on 2 Nov 2022
EPS came in at -$1.50 matching the estimated -$1.50, while revenue for the quarter reached $1.06M , missing expectations by -5.86%.
Earnings released on 11 Aug 2022
EPS came in at -$1.50 matching the estimated -$1.50, while revenue for the quarter reached $1.06M , beating expectations by +1.18K%.
Earnings released on 12 May 2022
EPS came in at -$1.50 matching the estimated -$1.50.
Earnings released on 8 Mar 2022
EPS came in at -$1.50 matching the estimated -$1.50, while revenue for the quarter reached -$33.30K , missing expectations by -107.40%.
Earnings released on 8 Nov 2021
EPS came in at -$1.50 matching the estimated -$1.50.
Earnings released on 10 Aug 2021
EPS came in at -$1.00 matching the estimated -$1.00.
Earnings released on 10 May 2021
EPS came in at -$1.50 matching the estimated -$1.50, while revenue for the quarter reached $33.33K , beating expectations by +66.67%.
Earnings released on 29 Mar 2021
EPS came in at -$1.50 matching the estimated -$1.50, while revenue for the quarter reached $62.50K .
Earnings released on 6 Nov 2020
EPS came in at -$1.50 matching the estimated -$1.50, while revenue for the quarter reached $95.83K .
MTNB Stock Performance
Access detailed MTNB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.